STOCK TITAN

Lineage Cell Therapeutics (LCTX) Stock News, Mar-Aug 2023

LCTX NYSE

Lineage Cell Therapeutics, Inc. develops allogeneic, or “off-the-shelf,” cell therapies for serious medical conditions using its AlloSCOPE cell differentiation and expansion platform. Its pipeline includes OpRegen, also known as RG6501, for geographic atrophy secondary to age-related macular degeneration; OPC1 for spinal cord injury; ReSonance, or ANP1, for hearing loss; and COR1 for corneal endothelial disease.

Recurring company news covers clinical data presentations, preclinical program launches, manufacturing and platform updates, research collaborations, milestone activity, financial results, business updates, and scientific governance. Updates frequently connect Lineage’s cell transplant programs with ophthalmology, neurology, auditory disease, and other non-oncology therapeutic areas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.11%
Tags
conferences earnings
Rhea-AI Summary

Lineage Cell Therapeutics (LCTX) presented positive results from their Phase 1/2a clinical study of OpRegen at the 2023 ARVO Annual Meeting. The study focused on patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Key findings include:

  • 7.6 letter gain in visual acuity observed in Cohort 4 over 12 months.
  • Long-term vision preservation noted up to 4 years in treated eyes.
  • Improved retinal structures correlated with the extent of OpRegen bleb coverage.

CEO Brian Culley expressed optimism about ongoing collaborations with Genentech and Roche. The ongoing Phase 2a study has started enrolling patients, highlighting the potential of OpRegen to address unmet medical needs in this debilitating condition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
-
Rhea-AI Summary

Lineage Cell Therapeutics announced that CEO Brian M. Culley will present at the 2023 American Association of Pharmaceutical Scientists National Biotechnology Conference on April 25, 2023, at 10:00 am ET. His presentation is part of the “Evolution of Cellular Therapy Symposium”, which features discussions on advancements in cellular therapies. The conference runs from April 23-26, 2023, at the Philadelphia Marriott Downtown Hotel. Lineage specializes in allogeneic cell therapies and operates on a robust cell therapy platform, with multiple product candidates in development, including therapies for age-related macular degeneration and acute spinal cord injuries.

For more details, visit www.lineagecell.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
conferences
-
Rhea-AI Summary

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation will host the 1st Annual Spinal Cord Injury Investor Symposium on June 29, 2023, in La Jolla, CA. This event aims to unify healthcare companies, policymakers, and investors to discuss innovations in spinal cord injury treatment. Confirmed speakers include experts from RUSH University Medical Center and the Reeve Foundation. Lineage's CEO emphasized the need for collaboration to improve recovery and mobility for spinal cord injury patients. The symposium will explore current treatment approaches and clinical trial participation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
Rhea-AI Summary

Lineage Cell Therapeutics announced the presentation of Phase 1/2a clinical study results for RG6501 (OpRegen) at the 2023 Retinal Cell and Gene Therapy Innovation Summit scheduled for April 21, 2023, in New Orleans, LA. OpRegen is being developed to treat geographic atrophy due to age-related macular degeneration (AMD) under a collaboration with Roche and Genentech. This therapy targets a compelling market need, as geographic atrophy affects over 5 million people globally, representing a significant opportunity for Lineage. The clinical presentation will be delivered by Eyal Banin, M.D., Ph.D., focusing on the implications of OpRegen in retinal therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags

FAQ

What is the current stock price of Lineage Cell Therapeutics (LCTX)?

Lineage Cell Therapeutics (LCTX) last closed at $0.7719.

What is the market cap of Lineage Cell Therapeutics (LCTX)?

The market cap of Lineage Cell Therapeutics (LCTX) is approximately $195.3M.